JPRN-UMIN000005549已完成1 期
Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study) - Cancer vaccine therapy using epitope peptide from CDH3 restricted to HLA-A*2402 with gemcitabine chemotherapy in patients with unresectable advanced pancreatic cancer (Phase I study)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Pregnancy or lactation 2)Patients with the intention of pregnancy. 3)Patients have uncontrollable severe infectional diseases. 4)Patients who are treated with steroid or immunotherapy during clinical trial. 5)Patients have uncontrollable multiple cancer. 6)Patients who have non-recovered injury. 7)Patients who have ileus and interstitial lung disiease. 8)Patients whom doctors define as inappropriate.
研究者
相似试验
已完成
1 期
Cancer vaccine therapy using epitope peptide from KIF20A restricted to HLA-A*24 in patients with pancreatic cancer refractory to standard therapy (Phase I/II study)pancreatic cancerJPRN-UMIN000004919Chiba Tokushukai Hospital30
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients with Non-small Cell Lung Cancer Refractory to Standard Therapy (Phase I study)on-small Cell Lung CancerJPRN-UMIN000003190Shiga University of Medical Science9
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*24 (CDCA1,KIF20A) in Patients with Small Cell Lung Cancer Refractory to Standard Therapy (Phase I study).Small Cell Lung CancerJPRN-UMIN000003191Shiga University of Medical Science9
已完成
1 期
Cancer Vaccine Therapy using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients with Non-small Cell Lung Cancer Refractory to Standard Therapy (Phase I study)on-small Cell Lung CancerJPRN-UMIN000003189Shiga University of Medical Science18
已完成
1 期
Cancer peptide vaccine therapy for patients with advanced metastatic colorectal cancer. Phase I/II clinical trial.Colorectal cancerJPRN-UMIN000004945Tokai University School of Medicine20